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ABSTRACT
Despite treatment with the current standard-
of-care therapies, patients with newly diagnosed 
glioblastoma multiforme (GBM) exhibit dismal 
prognoses. Bevacizumab has demonstrated 
activity in patients with recurrent GBM and 
phase 2 trials indicate that the combination 
of bevacizumab with standard-of-care therapy 
is feasible and active for patients with newly 
diagnosed GBM. Bevacizumab has been granted 
US approval for use as single-agent therapy for 
patients with progressive GBM following prior 
therapy, although it has not received approval 
for use in patients with GBM in Europe. Phase 
3 studies have been initiated in patients with 
newly diagnosed GBM and are currently 
recruiting patients. We describe the protocol for 
the AVAglio phase 3 registration trial, which is 
designed to evaluate the efficacy and safety of 
combining bevacizumab with standard-of-care 
therapy in patients with newly diagnosed GBM.
Keywords:  bevacizumab; clinical trial; 
glioblastoma multiforme; phase 3
INTRODUCTION
Population-based studies report a poor 
prognosis for patients with newly diagnosed 
glioblastoma multiforme (GBM), with 1-year, 
2-year, and 5-year survival rates at 17% to 30%, 
2% to 8%, and 1% to 3%, respectively.1,2 Despite 
recent advances in imaging techniques, surgery, 
and medical therapy,1 prognosis remains 
dismal. The current standard-of-care therapy 
(radiotherapy plus temozolomide followed by 
six cycles of adjuvant temozolomide) provided 
2-year and 5-year survival rates of 27% and 
10% for patients with newly diagnosed GBM in 
a clinical trial setting.3 While this indicates an 
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important improvement in survival benefit, a 
clear unmet clinical need still remains.
Bevacizumab (Avastin®, Genentech, Inc., San 
Francisco, CA, USA), a humanized monoclonal 
antibody that binds to and inhibits the activity 
of vascular endothelial growth factor (VEGF), 
acts with cytotoxic chemotherapy or biological 
agents in the treatment of various tumors, eg, 
colorectal, lung, renal, and breast cancer.4-7
GBM is characterized by sustained angiogenesis; 
the key regulator of tumor angiogenesis is 
VEGF, which is frequently overexpressed in 
GBM8,9 as well as other tumor types (Figure 
1). Bevacizumab inhibits VEGF10 and has been 
shown in preclinical models to have activity 
against GBM both alone and in combination 
with radiotherapy and temozolomide.11,12
Bevacizumab has also shown considerable 
potential to provide clinical benefit for patients 
with GBM (see below).
BEVACIZUMAB TRIAL DATA IN GBM
Various exploratory noncomparative clinical 
trials provided initial data suggesting that 
bevacizumab alone or in combination with 
irinotecan is active and has a manageable safety 
profile in patients with recurrent GBM.13,14
This benefit and safety profile was confirmed 
in a randomized, noncomparative phase 2 
Figure 1. Vascular endothelial growth factor mRNA overexpression by various tumor types detected on Affymetrix U133P 
microarray after staining in Affymetrix Fluidics station and scanning on GeneChip scanner 300 (data on file; Genentech, 
Inc., San Francisco, CA, USA). GBM=glioblastoma multiforme; NSCLC=non-small cell lung cancer; SCLC=small cell 
lung cancer; SD=standard deviation.
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trial (the BRAIN study; AVF3708g) in GBM 
patients following first or second recurrence 
after radiotherapy and temozolomide.15 In both 
the bevacizumab (n=85) and bevacizumab plus 
irinotecan (n=82) cohorts, respectively, the 
6-month progression-free survival (PFS) rate (43% 
and 50%), objective response rate (ORR; 28% 
and 38%), and median overall survival (OS; 9.2 
and 8.7 months) were compelling. Notably, ORR 
and 6-month PFS rate, the primary endpoints 
(assessed by independent radiologic review), were 
significantly (P<0.0001) higher than the rates of 
5% and 15%, respectively, expected with salvage 
chemotherapy according to external historical 
controls. Other clinical benefits observed in 
exploratory analyses included stabilization or 
reduction in dose of corticosteroids for patients 
receiving corticosteroids at baseline, and 
stabilization or improvement of neurocognitive 
function in responders, at the time of the 
response, and at week 24 in those who were 
progression free at 24 weeks or longer.16 No 
unexpected toxicities outside of the well 
established safety profile of bevacizumab were 
observed in the BRAIN study.15
Given the results with bevacizumab in 
patients with progressive GBM following prior 
therapy with radiation and temozolomide, 
studies were initiated to evaluate bevacizumab 
in combination with regional radiotherapy plus 
temozolomide as upfront treatment for patients 
with newly diagnosed GBM. Safety was deemed 
sufficiently acceptable in pilot studies of small 
numbers of patients17,18 to allow expansion to 
larger-scale phase 2 trials. 
In a noncomparative study in 70 patients 
with newly diagnosed GBM,19 bevacizumab 
in combination with radiotherapy plus 
temozolomide resulted in median OS and 
PFS of 19.6 and 13.6 months, respectively. In 
another nonrandomized phase 2 study,20 the 
current standard of care (radiotherapy plus 
temozolomide) was compared with (n=25) 
and without (n=31) bevacizumab in patients 
with newly diagnosed GBM. The 6-month 
PFS rate (87% vs. 52%), median PFS (12 vs. 
7 months, P=0.0001), 2-year OS rate (50% vs. 
22%), and median OS (24.0 vs. 17.5 months, 
P=0.09) were higher in the cohort receiving 
bevacizumab concurrently with standard 
therapy. Based on the known individual safety 
profile of bevacizumab, temozolomide, and 
radiotherapy, the investigators noted that 
toxicity of the combination was acceptable in 
the aforementioned studies. To date, there has 
been no full publication of controlled studies of 
bevacizumab in patients with recurrent GBM.
AVAGLIO TRIAL
A large, randomized, double-blind, placebo-
controlled, phase 3 trial (AVAglio, BO21990, 
NCT00943826) evaluating the addition of 
bevacizumab to the current standard of 
care (multimodal therapy of concurrent 
radiotherapy plus temozolomide followed by 
adjuvant temozolomide) is currently recruiting 
patients with newly diagnosed GBM (Figure 2). 
It is planning to recruit a total of approximately 
920 patients at approximately 140 centers 
worldwide.21,22 This study aims to determine 
the benefit to risk profile in newly diagnosed 
GBM patients.
Study Objectives
The coprimary endpoints of AVAglio are to 
demonstrate superior OS and PFS (investigator 
assessment) when bevacizumab is added to 
temozolomide with radiotherapy followed by 
temozolomide. Secondary endpoints are 1-year 
and 2-year survival rates, PFS by independent 
review facility (IRF), safety, and health-related 
quality of life (European Organization for 
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Research and Treatment of Cancer Quality of 
Life Questionnaire [EORTC QLQ-C30], BN20). 
Exploratory objectives include ORR based on 
adapted MacDonald criteria, response duration, 
OS and PFS stratified by O-6-methylguanine-DNA 
methyltransferase (MGMT) status, neurocognitive 
function using Mini Mental State Examination, 
corticosteroid use, signs and symptoms related 
to GBM, Karnofsky Performance Status, patterns 
of tumor progression, and biomarker analyses. 
The adapted MacDonald criteria that we defined 
take into account and clarify the evaluation of 
the nonenhancing component of the disease 
and the pseudoprogression issue, which share 
some concordance with recently proposed 
response assessment in neuro-oncology (RANO) 
criteria.23
Key Eligibility Criteria
Adult patients (≥18 years of age) with newly 
diagnosed supratentorial GBM histologically 
confirmed from surgical resection or biopsy 
tissue are eligible for enrolment into AVAglio. 
Study treatment has to be initiated >28 and 
<49 days following the last surgical procedure 
and a tumor tissue block has to be available for 
pathology central review and analysis of MGMT 
status. World Health Organization (WHO) 
performance status has to be ≤2. Corticosteroid 
dose has to be stable or decreasing within 5 days 
prior to randomization. Hematologic, hepatic, 
and renal function need to be adequate and 
blood coagulation parameters acceptable. 
The main exclusion criteria include: evidence 
of recent intracranial hemorrhage on magnetic 
resonance imaging; prior chemotherapy 
or immunotherapy for GBM or low-grade 
astrocytoma; prior radiotherapy to the brain; and 
history of intracranial abscess within 6 months 
prior to randomization, serious nonhealing 
wound, active ulcer, or untreated bone fracture.
Study Design and Therapy
Eligible patients are randomized (1:1) to the 
treatment arms (bevacizumab or placebo) under 
double-blind conditions after central stratification 
for recursive partitioning analysis class as defined 
by EORTC/NCI-C (3, 4, and 5) and region. All 
patients receive local irradiation (60 Gy total dose 
in 2 Gy fractions 5 days per week for 6 weeks) 
and temozolomide (75 mg/m2 orally from the 
first day to the last day of radiotherapy for a 
maximum of 49 days) during the concurrent 
phase, followed by a 4-week break from 
temozolomide therapy starting the day 
after the last dose of radiotherapy, and then 
adjuvant temozolomide (150-200 mg/m2 daily 
on days 1-5 of six 4-week cycles) during the 
maintenance phase. Bevacizumab (10 mg/kg 
intravenous [IV]) or placebo is administered 
every 2 weeks with concurrent radiotherapy/
temozolomide, with a dose on the last day of 
radiotherapy/temozolomide. Following a 4-week 
break, bevacizumab is continued every 2 weeks 
concomitantly with temozolomide maintenance. 
Single-agent bevacizumab (15 mg/kg IV) or 
placebo is continued every 3 weeks during the 
final monotherapy phase until disease progression 
or unacceptable toxicity (Figure 2). Dose selection 
was based on previous clinical experience and 
activity established with this dose.
Standard methods are followed for safety 
monitoring/recording and treatment delay/
dose modification/discontinuation. AVAglio 
will meet its primary objective if one or both 
of the coprimary endpoints (OS and PFS) is 
statistically significant.
CONCLUSION
Given the dismal prognosis of newly 
diagnosed GBM despite treatment with the 
current standard of care, any treatment that 
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Figure 2. AVAglio study design and treatment. PD=progressive disease; RPA=recursive partitioning analysis; 
RT=radiotherapy; TMZ=temozolomide.
delays disease progression with positive impact 
on functional status and quality of life, or 
extends survival, would be a valuable addition. 
Clinical data show that bevacizumab has activity 
and no unexpected toxicities in patients with 
recurrent GBM,14-16 and several phase 2 trials 
indicate that combining bevacizumab with 
standard-of-care therapy for newly diagnosed 
GBM is feasible and active.18-20 Some concern has 
arisen that bevacizumab may promote tumor 
invasion by upregulation of invasion-related 
genes,24 although data from recent studies do 
not support a propensity for bevacizumab to 
induce diffuse tumor growth or distant spread 
at recurrence.25,26
Bevacizumab has been granted US approval 
for use as a single agent for patients with 
progressive GBM following prior therapy but 
has not received approval for use in GBM 
in Europe because of the lack of controlled 
studies. The phase 3 AVAglio trial was therefore 
designed to evaluate the efficacy and safety of 
combining bevacizumab with standard-of-care 
therapy in patients with newly diagnosed 
GBM. This European registration trial is 
currently recruiting patients and results are 
awaited with interest. Another phase 3 study 
with a slightly different design conducted 
by the Radiation Therapy Oncology Group 
(NCT00884741) is ongoing in the USA in a 
similar patient population.27 
The results of these phase 3 studies will 
hopefully clarify any concerns with respect to 
bevacizumab therapy and determine the validity 
of combining bevacizumab with the current 
standard-of-care therapy in patients with newly 
diagnosed GBM. 
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